LA JOLLA - heute mit kräftigem Rebound?
Seite 1 von 2 Neuester Beitrag: 20.04.10 17:34 | ||||
| Eröffnet am: | 19.02.03 14:11 | von: Pavian1 | Anzahl Beiträge: | 43 |
| Neuester Beitrag: | 20.04.10 17:34 | von: Bersch1986 | Leser gesamt: | 8.289 |
| Forum: | Börse | Leser heute: | 1 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 > | ||||
Die Ergebnisse für das Medikament seien nicht so schlecht, wie dies der Kursrückgang vermuten liese, so die Analysten von Fulcrum. Das Medikament diene zur Behandlung einer bislang nicht sinnvoll therapierbaren Krankheit, hieß es. Auch habe das Testverfahren keine Sicherheitsrisiken des Medikamentes aufgezeigt. Sollte ein weiterer Testdurchlauf von Nöten sein, so wird dies vom Unternehmen finanziert werden können, so Fulcrum weiter. Die Analysten haben ein Kursziel von $26.
Denke nach dem Kursverfall gestern geht es heute einige % nach oben!! Ist noch jemand dabei??
Grüße
Pavian
SAN DIEGO, Mar 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), reported a net loss for the fourth quarter ended December 31, 2002 of $13.2 million or $0.31 per share (on 42.4 million weighted average shares) compared to a net loss of $6.7 million or $0.19 per share (on 35.3 million weighted average shares) for the fourth quarter of 2001. The net loss for the year ended December 31, 2002 was $43.3 million or $1.03 per share (on 42.0 million weighted average shares) compared to a net loss of $24.7 million or $0.71 per share (on 34.6 million weighted average shares) for the same period in 2001.
Research and development expenses increased to $11.3 million and $37.7 million for the three and twelve months ended December 31, 2002, respectively, compared to $5.9 million and $23.2 million for the comparable periods in 2001. The increase was primarily due to expenses associated with the Phase III clinical trial of Riquent(TM), the Company's lupus drug candidate, which was initiated in September 2000 and completed in December 2002, and the on-going open-label follow-on clinical trial of Riquent(TM), which was initiated in July 2002. The increase was also due to the Phase I/II clinical trial of LJP 1082, the Company's thrombosis drug candidate, which was initiated in November 2001 and completed in October 2002.
Cash, cash equivalents and short-term investments as of December 31, 2002 were $52.7 million compared to $47.0 million as of December 31, 2001. In January 2002, the Company sold 7.0 million shares of its common stock in a private placement for net proceeds of approximately $48.3 million. The Company anticipates that its existing cash, investments and interest earned thereon will be sufficient to fund the Company's operations as currently planned into the first quarter of 2004, assuming that it does not undertake significant commercialization activities for Riquent(TM).
Gruße
Pavian
PS: Gerade mit knapp 4% ins Plus gedreht in New York!
La Jolla Pharmaceutical Co.(NASDAQ-NMS:LJPC)
§ - San Diego
4th Quar Dec. 31:
2002 2001
Net income $(13,159,000) $(6,682,000)
Avg shrs (diluted) 42,427,000 35,255,000
Shr earns
Net income (.31) (.19)
Year:
Net income (43,318,000) (24,683,000)
Avg shrs (diluted) 42,046,000 34,604,000
Shr earns
Net income (1.03) (.71)
Figures in parentheses are losses.
La Jolla Pharmaceutical Co.(NASDAQ-NMS:LJPC) (LJPC) said research and development expenses grew to $11.3 million in the fourth quarter from $5.9 million a year earlier due to costs related to clincal trials of the company's Riquent lupus drug, as well as its thrombosis drug candidate.
La Jolla had $52.7 million in cash and equivalents at the end of the year, compared with $47 million at the end of 2001.
La Jolla expects to have enough cash for operations through the first quarter of 2004, assuming that it doesn't have significant commercialization for Riquent. In mid-February, La Jolla said that Phase III trials for Riquent didn't meet its primary endpoint.
-Kara Wetzel; Dow Jones Newswires; 201-938-5388
La Jolla Pharma kaufen
Global Biotech Investing
Zum Kauf von einigen Aktien der La Jolla Pharmaceutical Company (WKN 898844) raten die Experten vom Börsenbrief "Global Biotech Investing".
Aufgrund enttäuschender Ergebnisse des Wirkstoffs RIQUENT sei der Wert an einem Tag um 75% in die Tiefe gerauscht und habe in den Folgetagen weitere Verluste hinnehmen müssen. Diese Reaktion halte "Global Biotech Investing" für übertrieben.
Zwar habe das Medikament gegen Morbus Lupus nicht das Ziel der Phase III-Studie erreichen können, dennoch stünden die Chancen auf eine Zulassung durch die FDA nicht schlecht.
Denn bislang könne die Krankheit nicht vollständig geheilt werden und im Gegensatz zu Konkurrenzprodukten erreiche RIQUENT eine größere Linderung der Beschwerden und weise ein weitaus besseres Sicherheitsprofil aus.
Die nächste positive Meldung dürfte den Kurs wieder spürbar ansteigen lassen. Nach dem Kurseinbruch würden UBS Warburg, Morgan Keegan und Fortis den Wert zum Kauf empfehlen.
Eine kleine Startposition mit Aktien von La Jolla Pharma sollten sich interessierte Anleger nach Meinung der Experten von "Global Biotech Investing" ins Depot legen.
SAN DIEGO, Mar 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Chairman and Chief Executive Officer, Steven B. Engle, will present at the SG Cowen Securities Corporation 23rd Annual Health Care Conference at The Boston Marriott Copley Place, Boston, MA. Mr. Engle will present on Wednesday, March 19, 2003 at 10:15 a.m. and again at 11:15 a.m. Eastern time. An audio webcast of the presentation will be available via the Company's web site at www.ljpc.com or at SG Cowen's web site at www.sgcowen.com .
La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases afflicting several million people in the United States and Europe. The Company is developing Riquent(TM), formerly known as LJP 394, for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing LJP 1082 for the treatment of antibody-mediated thrombosis, a condition in which patients suffer from recurrent stroke, deep-vein thrombosis and other thrombotic events. The Company's common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: http://www.ljpc.com .
Warburg thinks the Phase III trials will have to be repeated. The company doesn't have sufficient money to repeat the trial.
Charttechnisch sollten wir das Tief eigentlich geseh´n haben. Die Marke um USD 1,40 sollten wir nicht mehr unterbieten. Auch Fast- u. Low Stochastic im überverkauften Bereich!!!!
Bei Ausbruch aus dem Abwärtstrend seit dem Hoch Anfang Dezember sollte es ziemlich schnell nach oben geh´n.
Fundamental ist´s aber etwas riskant - erste Entscheidungen der FDA sollten noch dieses Monat fallen - falls diese wieder negativ zur Zulassung zum Medikament Riquent ausfällt, geht´s sicher unter 1 USD. Bei Zulassung gibt´s kein halten für den Kurs.
Positiv sehe ich den Insiderkauf von 77k Shares von Gonzales Alejandro.
Alles in allem ein gutes Chance/Risiko Verhältnis
xpfuture
Angehängte Grafik:
La_Jolla_Pharma.png (verkleinert auf 85%)
La_Jolla_Pharma.png (verkleinert auf 85%)
Monday March 14, 7:30 am ET
SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - News) today announced that, based on the outcome of a meeting with the United States Food and Drug Administration (FDA) on March 11, 2005, its treatment for lupus renal disease, Riquent® (abetimus sodium), is unlikely to receive an accelerated approval under the FDA's Subpart H regulation. The Company plans to continue the ongoing clinical benefit trial and expects to continue discussions with the FDA about ways to enhance the trial, including, as previously announced, the addition of a higher dose to the study.
ADVERTISEMENT
This decision follows a number of meetings with the FDA since October 2004, when the Company received an Approvable Letter from the FDA for Riquent. The Approvable Letter indicated that an additional trial demonstrating clinical benefit would be required prior to approval of Riquent and that the Company's ongoing trial, initiated in August 2004, would appear to satisfy this requirement.
"We are disappointed that the FDA determined that accelerated approval is not applicable to the approval of Riquent," stated Steve Engle, Chairman and CEO of La Jolla Pharmaceutical Company. "We recognize the urgent need for safer and more effective treatments for lupus patients, as no new drugs have been approved for this disease in the United States in almost 40 years."
xpfuture
LaJolla Pharmaceutical Co. said the Food and Drug Administration has granted 'fast track' status for its Riquent treatment of lupus renal disease. The company said it currently only has limited financial resources and if it does not receive funding from a collaborative agreement or obtain other financing in the near future, it will not have sufficient resources to complete the ongoing clinical benefit trial or to continue its operations beginning in the first quarter of 2006.
Optionen
| Boardmail an "pomerol" |
Wertpapier: La Jolla Pharmaceutical |
Topper J. (Mananger bei LJPC) hat sich 20 Mio. Stk. ins Depot gelegt:
http://www.sec.gov/Archives/edgar/data/920465/.../xslF345X02/doc4.xml
xpfuture
